

Actinogen Medical Ltd

11:30 24 Apr 2015

Actinogen Medical raises \$10M for Alzheimer's drug trial

Sydney based Actinogen Medical (ASX:ACW) has raised \$10.0 million to further a trial of its very promising drug to fight Alzheimer's disease.

The funds were raised in a placement which saw heavy investor demand at an issue price of \$0.095 per share.

The Phase 2 trial of its drug Xanamem™ is planned to start in 2016 and for it to run in Australia/New Zealand, the USA and the UK.

Xanamem blocks cortisol production which is a key plank in the fight against Alzheimer's disease to stop the disease at an early stage.

Excess cortisol is associated with memory loss and amyloid plaques, hallmarks of Alzheimer's disease.

The capital raising will also be used to support the IND filing with US FDA.

A share purchase plan will also raise an additional \$1 million.

Alzheimer's disease is the most common form of dementia and has a debilitating effect on patients and families. At present, there is no viable cure for sufferers.

Alzheimer's is now the second leading cause of death in Australia behind ischaemic heart disease.

Estimates by the American Alzheimer's Association indicate that the direct healthcare cost of the disease was \$US250 billion in 2013.

This is projected to rise to over \$US1 trillion by 2050, outstripping the cost of treating all other diseases.

Price: A\$0.049

Market Cap: A\$34.63M

1 Year Share Price Graph



Share Information

Code: ACW

Listing: ASX

52 week High Low
0.059p0352941176p

Sector: Pharma & Biotech

Website: www.actinogen.com.au

Company Synopsis:

Actinogen Medical Ltd (ASX:ACW) is listed on the Australian Securities Exchange.

Author:

Proactive Investors Australia

+61 (0)2 9280 0700

action@proactiveinvestors.com.au

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.